Glenn Steele, Jr. Biography and Net Worth

Director of PTC Therapeutics

Dr. Steele has served as a member of our Board since 2015. Dr. Steele has served as the Chairman of xG Health Solutions, a health care redesign and optimization company affiliated with Geisinger Health System, from 2013 to 2018. From 2001 until 2015, Dr. Steele served as President and Chief Executive Officer of Geisinger Health System, an integrated health services organization in central and northeastern Pennsylvania. Dr. Steele previously served as the dean of the Biological Sciences Division and the Pritzker School of Medicine and vice president for medical affairs at the University of Chicago, as well as the Richard T. Crane Professor in the Department of Surgery. Prior to that, he was the William V. McDermott Professor of Surgery at Harvard Medical School, president and chief executive officer of Deaconess Professional Practice Group, Boston, MA, and chairman of the department of surgery at New England Deaconess Hospital (Boston, MA). Dr. Steele has served on the board of directors of several companies, including Wellcare Health Plans Inc., a NYSE-listed managed care company, from 2009 to 2019.

What is Glenn Steele, Jr.'s net worth?: The estimated net worth of Glenn Steele, Jr. is at least $1.43 million as of September 30th, 2026. Dr. Steele, Jr. owns 22,500 shares of PTC Therapeutics stock worth more than $1,427,850 as of October 4th. This net worth evaluation does not reflect any other investments that Dr. Steele, Jr. may own. Learn More about Glenn Steele, Jr.'s net worth.
How do I contact Glenn Steele, Jr.?: The corporate mailing address for Dr. Steele, Jr. and other PTC Therapeutics executives is 500 Warren Corporate Center Drive, Warren, NJ, 07059. PTC Therapeutics can also be reached via phone at (908) 222-7000 and via email at [email protected]. Learn More on Glenn Steele, Jr.'s contact information.
Has Glenn Steele, Jr. been buying or selling shares of PTC Therapeutics?: Glenn Steele, Jr. has not been actively trading shares of PTC Therapeutics in the last ninety days. Most recently, Glenn Steele, Jr. sold 12,000 shares of the business's stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $65.16, for a transaction totalling $781,920.00. Following the completion of the sale, the director now directly owns 22,500 shares of the company's stock, valued at $1,466,100. Learn More on Glenn Steele, Jr.'s trading history.
Who are PTC Therapeutics' active insiders?: PTC Therapeutics' insider roster includes Neil Almstead (Insider), Mark Boulding (VP), Lee Golden (Chief Medical Officer), Pierre Gravier (CFO), Emily Hill (CFO), Allan Jacobson (Director), Matthew Klein (COO), Stephanie Okey (Director), Eric Pauwels (Insider), Stuart Peltz (CEO), Emma Reeve (Director), Michael Schmertzler (Director), Mary Smith (Director), David Southwell (Director), Glenn Steele, Jr. (Director), Dawn Svoronos (Director), Christine Utter (CAO), Alethia Young (Chief Financial Officer, Bicycle Therapeutics), and Jerome Zeldis (Director). Learn More on PTC Therapeutics' active insiders.
Are insiders buying or selling shares of PTC Therapeutics?: During the last twelve months, insiders at the biopharmaceutical company sold shares 85 times. They sold a total of 707,582 shares worth more than $54,352,888.03. The most recent insider tranaction occured on September, 30th when Director Glenn Steele, Jr. sold 12,000 shares worth more than $781,920.00. Insiders at PTC Therapeutics own 5.3% of the company. Learn More about insider trades at PTC Therapeutics.
Information on this page was last updated on 9/30/2026.

Glenn Steele, Jr. Insider Trading History at PTC Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/30/2026	Sell	12,000	$65.16	$781,920.00	22,500
1/2/2026	Sell	12,000	$76.35	$916,200.00	18,500

Glenn Steele, Jr. Buying and Selling Activity at PTC Therapeutics

PTC Therapeutics Company Overview

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Today's Range

Now: $63.46

$62.80

$65.39

50 Day Range

MA: $69.39

$62.28

$75.80

2 Week Range

Now: $63.46

$61.23

$90.87

Volume

895,553 shs

Average Volume

1,230,140 shs

Market Capitalization

$5.30 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.49